FOJCY vs. RPRX
FOJCY (Fortum Oyj ADR) and RPRX (Royalty Pharma plc) are both stocks. FOJCY operates in Utilities - Renewable (Utilities), while RPRX operates in Biotechnology (Healthcare). Over the past 5 years, FOJCY returned 2.71%/yr vs 11.45%/yr for RPRX. Their 0.08 correlation means their historical movements had little consistent relationship.
Performance
FOJCY vs. RPRX - Performance Comparison
Loading charts...
Returns By Period
In the year-to-date period, FOJCY achieves a 3.51% return, which is significantly lower than RPRX's 52.68% return.
FOJCY
- 1D
- -1.58%
- 1M
- -2.89%
- 6M
- -7.31%
- YTD
- 3.51%
- 1Y
- 19.66%
- 3Y*
- 30.66%
- 5Y*
- 2.71%
- 10Y*
- 11.94%
- ALL TIME*
- 8.33%
RPRX
- 1D
- -1.00%
- 1M
- 1.14%
- 6M
- 41.54%
- YTD
- 52.68%
- 1Y
- 60.83%
- 3Y*
- 26.97%
- 5Y*
- 11.45%
- 10Y*
- —
- ALL TIME*
- 7.03%
Liquidity Comparison
| Position | Avg. Volume Value (2W) | Avg. Volume Value (1M) | Avg. Volume Value (3M) |
|---|---|---|---|
FOJCY Fortum Oyj ADR | $34.03K | $32.87K | $39.10K |
| $153.39M | $158.93M | $200.87M |
FOJCY vs. RPRX - Yearly Performance Comparison
| 2026 (YTD) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | |
|---|---|---|---|---|---|---|---|
FOJCY Fortum Oyj ADR | 3.51% | 79.68% | 2.92% | -5.53% | -44.41% | 40.46% | 28.34% |
RPRX Royalty Pharma plc | 52.68% | 55.29% | -6.36% | -27.08% | 0.99% | -19.09% | 14.62% |
Correlation
The correlation between FOJCY and RPRX is 0.03, meaning there was essentially no consistent relationship between their historical price movements. Each responded to its own set of market drivers.
| Correlation | |
|---|---|
Correlation (1Y) Focuses on recent behavior, but can change the most. | 0.03 |
Correlation (3Y) Balances recent behavior with more history. | 0.08 |
Correlation (5Y) Shows whether the relationship held over a longer period. | 0.09 |
Correlation (All Time) Calculated using the full available price history since Jun 16, 2020 | 0.08 |
Fundamentals
FOJCY:
$98.03B
RPRX:
$25.13B
FOJCY:
€0.18
RPRX:
$2.22
FOJCY:
20.54
RPRX:
26.34
FOJCY:
3.10
RPRX:
8.93
FOJCY:
€5.49B
RPRX:
$2.44B
FOJCY:
€1.99B
RPRX:
$1.81B
FOJCY:
€1.49B
RPRX:
$1.70B
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Return for Risk
FOJCY vs. RPRX — Risk / Return Rank
FOJCY
RPRX
FOJCY vs. RPRX - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for Fortum Oyj ADR (FOJCY) and Royalty Pharma plc (RPRX). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| FOJCY | RPRX | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | -2.19 | ||
| Sortino ratioReturn per unit of downside risk | -2.50 | ||
| Omega ratioGain probability vs. loss probability | 1.12 | 1.45 | -0.33 |
| Calmar ratioReturn relative to maximum drawdown | 1.32 | 8.47 | -7.14 |
| Martin ratioReturn relative to average drawdown | 3.04 | 20.69 | -17.66 |
Loading charts...
Drawdowns
FOJCY vs. RPRX - Drawdown Comparison
The maximum FOJCY drawdown since its inception was -70.67%, which is greater than RPRX's maximum drawdown of -49.68%. Use the drawdown chart below to compare losses from any high point for FOJCY and RPRX.
Loading charts...
Drawdown Indicators
| FOJCY | RPRX | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -70.67% | -49.68% | -20.99% |
Max Drawdown (1Y)Largest decline over 1 year | -18.79% | -7.38% | -11.41% |
Max Drawdown (3Y)Largest decline over 3 years | -25.89% | -20.67% | -5.22% |
Max Drawdown (5Y)Largest decline over 5 years | -70.67% | -41.98% | -28.69% |
Max Drawdown (10Y)Largest decline over 10 years | -70.67% | — | — |
Current DrawdownCurrent decline from peak | -17.08% | -2.57% | -14.51% |
Average DrawdownAverage peak-to-trough decline | -24.91% | -25.78% | +0.87% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 8.18% | 3.01% | +5.17% |
Volatility
FOJCY vs. RPRX - Volatility Comparison
Fortum Oyj ADR (FOJCY) has a higher volatility of 10.80% compared to Royalty Pharma plc (RPRX) at 7.73%. This indicates that FOJCY's price experiences larger fluctuations and is considered to be riskier than RPRX based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Loading charts...
Volatility by Period
| FOJCY | RPRX | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | 10.80% | 7.73% | +3.07% |
Volatility (6M)Calculated over the trailing 6-month period | 34.06% | 15.78% | +18.28% |
Volatility (1Y)Calculated over the trailing 1-year period | 45.85% | 22.90% | +22.95% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 48.77% | 23.86% | +24.91% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 42.28% | 26.84% | +15.44% |
Dividends
FOJCY vs. RPRX - Dividend Comparison
FOJCY's dividend yield for the trailing twelve months is around 3.90%, more than RPRX's 1.56% yield.
| Position | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
FOJCY Fortum Oyj ADR | 3.90% | 6.94% | 9.39% | 6.74% | 7.57% | 4.22% | 7.37% | 4.88% | 6.47% | 11.86% | 16.86% | 9.06% |
RPRX Royalty Pharma plc | 1.56% | 2.28% | 3.29% | 2.85% | 1.92% | 1.71% | 0.60% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Financials
FOJCY vs. RPRX - Financials Comparison
This section allows you to compare key financial metrics between Fortum Oyj ADR and Royalty Pharma plc. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities
FOJCY vs. RPRX - Profitability Comparison
FOJCY - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on Aug 2026, Fortum Oyj ADR reported a gross profit of 400.00M and revenue of 1.12B. Therefore, the gross margin over that period was 35.6%.
RPRX - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on Aug 2026, Royalty Pharma plc reported a gross profit of 0.00 and revenue of 631.00M. Therefore, the gross margin over that period was 0.0%.
FOJCY - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on Aug 2026, Fortum Oyj ADR reported an operating income of 107.00M and revenue of 1.12B, resulting in an operating margin of 9.5%.
RPRX - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on Aug 2026, Royalty Pharma plc reported an operating income of 563.00M and revenue of 631.00M, resulting in an operating margin of 89.2%.
FOJCY - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on Aug 2026, Fortum Oyj ADR reported a net income of 109.00M and revenue of 1.12B, resulting in a net margin of 9.7%.
RPRX - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on Aug 2026, Royalty Pharma plc reported a net income of 295.00M and revenue of 631.00M, resulting in a net margin of 46.8%.
Frequently Asked Questions
FOJCY and RPRX have a correlation of 0.03, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.
FOJCY has higher volatility (10.80%) compared to RPRX (7.73%). In terms of maximum drawdown, FOJCY dropped -70.67% vs RPRX's -49.68%.
RPRX currently has the higher Sharpe Ratio (2.73 vs 0.54), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.
Find the right allocation for FOJCY and RPRX
Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Optimizer